SILENCE THERAPEUTICS PLC-ADR (SLN)
US82686Q1013 - ADR
Oversold Conditions For Silence Therapeutics (SLN)
Silence Therapeutics Presents Promising Phase 1 Data in Polycythemia Vera Patients at the American Society of Hematology (ASH) Annual Meeting
Silence Therapeutics to Participate in Fireside Chat at Piper Sandler 36th Annual Healthcare Conference
Silence Therapeutics Presents Late-Breaking Phase 2 Zerlasiran Data at 2024 American Heart Association (AHA) Annual Meeting
Silence Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
Silence Therapeutics Becomes Oversold (SLN)
Silence Therapeutics to Participate in Fireside Chat at the Jefferies London Healthcare Conference
Silence Therapeutics to Webcast Presentations at Upcoming September Investor Conferences
SLN Stock Earnings: Silence Therapeutics Reported Results for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Silence Therapeutics (NASDAQ:SLN) just reported results for the second quarter ...
SLN Stock Earnings: Silence Therapeutics Reported Results for Q2 2024
Silence Therapeutics just reported results for the second quarter of 2024.
Silence Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
The 3 Best Gene Editing Stocks to Buy in August 2024
These are the best gene-editing stocks to buy as the biotechs pursue precision therapies to cure rare diseases.
SLN Makes Notable Cross Below Critical Moving Average
Morgan Stanley Predicts Triple-Digit Rally for These 3 Stocks
It takes a special set of circumstances for high-growth stocks to double in value in one year but analyst says these three can do it.
SLN Crosses Below Key Moving Average Level
Silence Therapeutics Announces Positive Results from Ongoing SANRECO Phase 1 Study of Divesiran in Polycythemia Vera Patients
Silence Therapeutics Achieves $2 Million Research Milestone Payment from Hansoh Pharma Collaboration
Silence Therapeutics Announces Positive Topline 48-Week Data from Phase 2 Study of Zerlasiran in Patients with Elevated Lipoprotein(a)
Silence Therapeutics to Present at Jefferies Global Healthcare Conference
SLN Stock Earnings: Silence Therapeutics Reported Results for Q1 2024
Silence Therapeutics just reported results for the first quarter of 2024.
SLN Stock Earnings: Silence Therapeutics Reported Results for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Silence Therapeutics (NASDAQ:SLN) just reported results for the first quarter o...
Silence Therapeutics Reports First Quarter 2024 Results and Highlights Pipeline Progress
Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright 2nd Annual BioConnect Investor Conference
Silence Therapeutics Announces Retirement of Alistair Gray from Board of Directors
3 Biotech Stocks to Turn $5,000 Into $1 Million: April 2024
Biotech stocks can offer some of the most explosive, exciting opportunities on the market.That is, if you find the right one.
Silence Therapeutics Announces JAMA Publication of Additional Phase 1 Data for Zerlasiran in Subjects with Elevated Lipoprotein(a)
7 Biotech Stocks Ready to Ride the Sector’s Resurgence
With investors seeking new opportunities with certain segments appearing stretched, biotech stocks offer a viable canvas.
These Analysts Boost Their Forecasts On Silence Therapeutics After Full Year 2023 Results
Silence Therapeutics Plc (NASDAQ: SLN) reported a loss for 2023 on Wednesday.